STOCK TITAN

[Form 4] Bolt Biotherapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Bolt Biotherapeutics (BOLT) disclosed insider equity activity by its President, CEO and CFO, William P. Quinn. On 10/22/2025, he acquired 40,000 restricted stock units (RSUs) for $0. Each RSU represents one share of common stock at settlement, and the award vests in full on September 15, 2026, assuming continued employment.

Earlier, on 06/06/2025, Quinn purchased 125 shares of common stock at $5.492 per share under the company’s Employee Stock Purchase Plan, which is exempt under Rule 16b-3(c). After the reported transactions, he beneficially owned 42,188 shares directly.

Bolt Biotherapeutics (BOLT) ha rivelato attività insider di equity da parte del suo Presidente, CEO e CFO, William P. Quinn. Il 22/10/2025 ha acquistato 40.000 unità azionarie vincolate (RSU) per $0. Ogni RSU rappresenta una azione ordinaària al regolamento, e l'assegnazione veste completamente il 15 settembre 2026, salvo mantenimento dell'impiego.

In precedenza, il 06/06/2025, Quinn ha acquistato 125 azioni di azioni ordinarie a $5.492 per azione nell'ambito del piano di acquisto di azioni per dipendenti della società, che è esente secondo la Rule 16b-3(c). Dopo le transazioni riportate, possedeva direttamente 42.188 azioni.

Bolt Biotherapeutics (BOLT) divulgó actividad de participación interna por parte de su presidente, director ejecutivo y director financiero, William P. Quinn. El 22/10/2025 adquirió 40.000 unidades de acciones restringidas (RSU) por $0. Cada RSU representa una acción común en el momento de la liquidación, y la adjudicación vence en su totalidad el 15 de septiembre de 2026, siempre que continúe empleado.

Anteriormente, el 06/06/2025, Quinn compró 125 acciones de acciones comunes a $5.492 por acción bajo el Plan de Compra de Acciones para Empleados de la compañía, que está exento según la Regla 16b-3(c). Después de las transacciones reportadas, él poseía beneficiosamente 42.188 acciones directamente.

볼트 생물치료제(BOLT)는 회장 겸 CEO이자 CFO인 윌리엄 P. 퀸의 내부자 지분 활동을 공시했습니다. 2025-10-22에 그는 40,000주 제한 주식단위(RSU)$0에 취득했습니다. 각 RSU는 정산 시 보통주 1주를 나타내며, 수여는 고용이 지속된다는 가정 하에 2026년 9월 15일에 전액 취득합니다.

이전에 2025-06-06에 퀸은 회사의 직원주식매수제도(Employee Stock Purchase Plan) 하에 주당 $5.492125주의 보통주를 매수했고, 이는 Rule 16b-3(c)에 따라 면제됩니다. 보고된 거래 이후 그는 직접적으로 42,188주를 지배적으로 보유했습니다.

Bolt Biotherapeutics (BOLT) a dévoilé une activité d’initié de ses actions par son président, PDG et directeur financier, William P. Quinn. Le 22/10/2025, il a acquis 40 000 unités d’actions restreintes (RSU) pour $0. Chaque RSU représente une action ordinaire à la liquidation, et la attribution se vest pleinement le 15 septembre 2026, sous réserve du maintien de l’emploi.

Plus tôt, le 06/06/2025, Quinn a acheté 125 actions ordinaires à $5,492 par action dans le cadre du plan d’achat d’actions des employés de la société, qui est exonéré en vertu de la règle 16b-3(c). Après les transactions rapportées, il détenait directement 42 188 actions bénéficiaires.

Bolt Biotherapeutics (BOLT) offenbarte Insider-Aktienaktivitäten durch Präsidenten, CEO und CFO William P. Quinn. Am 2025-10-22 erwarb er 40.000 Restricted Stock Units (RSUs) für $0. Jede RSU repräsentiert eine Stammaktie bei Abwicklung, und die Zuteilung vestet vollständig am 15.9.2026, vorbehaltlich weiteren Arbeitsverhältnisses.

Zuvor, am 06.06.2025, kaufte Quinn 125 Aktien Stammaktien zu $5,492 pro Aktie im Rahmen des Unternehmens Employee Stock Purchase Plans, der gemäß Regel 16b-3(c) befreit ist. Nach den gemeldeten Transaktionen hielt er direkt 42.188 Aktien vorteilhaft.

أعلن Bolt Biotherapeutics (BOLT) عن نشاط أسهم داخلي لرئيسه والمدير التنفيذي والمالي، وليام ب. كوين. في 2025-10-22 اشترى 40,000 وحدة أسهم مقيدة (RSUs) بسعر $0. تمثل كل RSU سهماً عادياً عند التسوية، وتُكتمل منحها بحلول 15 سبتمبر 2026، بشرط استمرار العمل.

في وقت سابق، في 2025-06-06, اشترى كوين 125 سهماً من الأسهم العادية بسعر $5.492 للسهم بموجب خطة شراء أسهم الموظفين للشركة، وهي معفاة وفق القاعدة 16b-3(c). بعد الصفقات المذكورة، كان يمتلك مباشرةً 42,188 سهماً.

Positive
  • None.
Negative
  • None.

Bolt Biotherapeutics (BOLT) ha rivelato attività insider di equity da parte del suo Presidente, CEO e CFO, William P. Quinn. Il 22/10/2025 ha acquistato 40.000 unità azionarie vincolate (RSU) per $0. Ogni RSU rappresenta una azione ordinaària al regolamento, e l'assegnazione veste completamente il 15 settembre 2026, salvo mantenimento dell'impiego.

In precedenza, il 06/06/2025, Quinn ha acquistato 125 azioni di azioni ordinarie a $5.492 per azione nell'ambito del piano di acquisto di azioni per dipendenti della società, che è esente secondo la Rule 16b-3(c). Dopo le transazioni riportate, possedeva direttamente 42.188 azioni.

Bolt Biotherapeutics (BOLT) divulgó actividad de participación interna por parte de su presidente, director ejecutivo y director financiero, William P. Quinn. El 22/10/2025 adquirió 40.000 unidades de acciones restringidas (RSU) por $0. Cada RSU representa una acción común en el momento de la liquidación, y la adjudicación vence en su totalidad el 15 de septiembre de 2026, siempre que continúe empleado.

Anteriormente, el 06/06/2025, Quinn compró 125 acciones de acciones comunes a $5.492 por acción bajo el Plan de Compra de Acciones para Empleados de la compañía, que está exento según la Regla 16b-3(c). Después de las transacciones reportadas, él poseía beneficiosamente 42.188 acciones directamente.

볼트 생물치료제(BOLT)는 회장 겸 CEO이자 CFO인 윌리엄 P. 퀸의 내부자 지분 활동을 공시했습니다. 2025-10-22에 그는 40,000주 제한 주식단위(RSU)$0에 취득했습니다. 각 RSU는 정산 시 보통주 1주를 나타내며, 수여는 고용이 지속된다는 가정 하에 2026년 9월 15일에 전액 취득합니다.

이전에 2025-06-06에 퀸은 회사의 직원주식매수제도(Employee Stock Purchase Plan) 하에 주당 $5.492125주의 보통주를 매수했고, 이는 Rule 16b-3(c)에 따라 면제됩니다. 보고된 거래 이후 그는 직접적으로 42,188주를 지배적으로 보유했습니다.

Bolt Biotherapeutics (BOLT) a dévoilé une activité d’initié de ses actions par son président, PDG et directeur financier, William P. Quinn. Le 22/10/2025, il a acquis 40 000 unités d’actions restreintes (RSU) pour $0. Chaque RSU représente une action ordinaire à la liquidation, et la attribution se vest pleinement le 15 septembre 2026, sous réserve du maintien de l’emploi.

Plus tôt, le 06/06/2025, Quinn a acheté 125 actions ordinaires à $5,492 par action dans le cadre du plan d’achat d’actions des employés de la société, qui est exonéré en vertu de la règle 16b-3(c). Après les transactions rapportées, il détenait directement 42 188 actions bénéficiaires.

Bolt Biotherapeutics (BOLT) offenbarte Insider-Aktienaktivitäten durch Präsidenten, CEO und CFO William P. Quinn. Am 2025-10-22 erwarb er 40.000 Restricted Stock Units (RSUs) für $0. Jede RSU repräsentiert eine Stammaktie bei Abwicklung, und die Zuteilung vestet vollständig am 15.9.2026, vorbehaltlich weiteren Arbeitsverhältnisses.

Zuvor, am 06.06.2025, kaufte Quinn 125 Aktien Stammaktien zu $5,492 pro Aktie im Rahmen des Unternehmens Employee Stock Purchase Plans, der gemäß Regel 16b-3(c) befreit ist. Nach den gemeldeten Transaktionen hielt er direkt 42.188 Aktien vorteilhaft.

أعلن Bolt Biotherapeutics (BOLT) عن نشاط أسهم داخلي لرئيسه والمدير التنفيذي والمالي، وليام ب. كوين. في 2025-10-22 اشترى 40,000 وحدة أسهم مقيدة (RSUs) بسعر $0. تمثل كل RSU سهماً عادياً عند التسوية، وتُكتمل منحها بحلول 15 سبتمبر 2026، بشرط استمرار العمل.

في وقت سابق، في 2025-06-06, اشترى كوين 125 سهماً من الأسهم العادية بسعر $5.492 للسهم بموجب خطة شراء أسهم الموظفين للشركة، وهي معفاة وفق القاعدة 16b-3(c). بعد الصفقات المذكورة، كان يمتلك مباشرةً 42,188 سهماً.

Bolt Biotherapeutics(BOLT)披露了其总裁、首席执行官兼首席财务官William P. Quinn的内部人股权活动。于2025-10-22他以$0购买了40,000份受限股票单位(RSU)。每份RSU在结算时代表一股普通股,且该奖励在2026年9月15日全部归属,前提是继续就职。

此前,在2025-06-06,Quinn以每股$5.492的价格通过公司的员工股票购买计划购买了125股普通股,该计划根据规则16b-3(c)豁免。报道的交易之后,他直接实际拥有42,188股

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Quinn William P.

(Last) (First) (Middle)
C/O BOLT BIOTHERAPEUTICS, INC.
900 CHESAPEAKE DRIVE

(Street)
REDWOOD CITY CA 94063

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President, CEO and CFO
3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/06/2025 P 125(1) A $5.492 2,188 D
Common Stock 10/22/2025(2) (3) A 40,000 A $0(2) 42,188 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares acquired under the issuer's Employee Stock Purchase Plan and therefore exempt under Rule 16b-3(c)
2. The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
3. The restricted stock units subject to the award will vest in full on September 15, 2026, assuming continued employment through such date.
/s/ William P. Quinn 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BOLT report on this Form 4?

William P. Quinn acquired 40,000 RSUs on 10/22/2025 for $0, and previously bought 125 shares at $5.492 on 06/06/2025.

When do the newly granted BOLT RSUs vest?

The 40,000 RSUs vest in full on September 15, 2026, assuming continued employment.

How many BOLT shares does the reporting person own after these transactions?

Following the transactions, William P. Quinn beneficially owned 42,188 shares directly.

What is the price associated with the RSU grant reported by BOLT?

The RSUs were received for $0 consideration; each RSU represents one share at settlement.

What was the price paid for shares purchased under BOLT’s ESPP?

On 06/06/2025, 125 shares were purchased at $5.492 per share under the ESPP.

Who is the reporting person and what is their role at BOLT?

The reporting person is William P. Quinn, who serves as President, CEO and CFO, and is also a Director.
Bolt Biotherapeutics, Inc.

NASDAQ:BOLT

BOLT Rankings

BOLT Latest News

BOLT Latest SEC Filings

BOLT Stock Data

11.06M
1.88M
2.26%
44.61%
4.06%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY